Detection of minimal or measurable residual disease (MRD) in acute lymphoid leukemia
(ALL) post induction or consolidation has significant prognostic and treatment implications …

Measurable (minimal) residual disease (MRD) status in acute lymphoblastic leukemia (ALL)
has largely superseded the importance of traditional risk factors for ALL, such as baseline …

In recent years, the identification of minimal residual disease (MRD) that persists after
chemotherapy has emerged as the most powerful tool in determining the prognosis of …

Measurement of submicroscopic (minimal) levels of residual disease (MRD) can be used to
monitor treatment response much more precisely than morphological screening of bone …

Measurable residual disease (MRD) is the most powerful independent predictor of risk of
relapse and long-term survival in adults and children with acute lymphoblastic leukemia …

In patients with acute lymphoblastic leukemia (ALL), treatment response is increasingly
evaluated with minimal residual disease (MRD) assays. ALL cells can be recognized by …

During the past 2 decades, there has been considerable progress in the treatment of both
childhood and adult acute lymphocytic leukemia (ALL). Currently, 70% to 90% of adults …

Minimal or measurable residual disease (MRD) is the most important independent
prognostic factor for patients with acute lymphoblastic leukemia (ALL). Post-treatment MRD …

In patients with acute lymphoblastic leukemia (ALL), monitoring of minimal residual disease
(MRD) offers a way to precisely assess early treatment response and detect relapse …

Although many clinical and laboratory features have prognostic significance in acute
lymphoblastic leukemia (ALL), the most important one is response to treatment as measured …